HRP20150312T1 - Rekombinantni n-glikozilirani proteini iz prokariotskih stanica - Google Patents
Rekombinantni n-glikozilirani proteini iz prokariotskih stanica Download PDFInfo
- Publication number
- HRP20150312T1 HRP20150312T1 HRP20150312TT HRP20150312T HRP20150312T1 HR P20150312 T1 HRP20150312 T1 HR P20150312T1 HR P20150312T T HRP20150312T T HR P20150312TT HR P20150312 T HRP20150312 T HR P20150312T HR P20150312 T1 HRP20150312 T1 HR P20150312T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- protein
- spp
- aeruginosa
- oligo
- Prior art date
Links
- 108091006036 N-glycosylated proteins Proteins 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract 12
- 150000001413 amino acids Chemical group 0.000 claims abstract 5
- 150000004676 glycans Chemical class 0.000 claims 6
- 108091035707 Consensus sequence Proteins 0.000 claims 3
- 150000002482 oligosaccharides Polymers 0.000 claims 3
- 229920001282 polysaccharide Polymers 0.000 claims 3
- 239000005017 polysaccharide Substances 0.000 claims 3
- 241000894006 Bacteria Species 0.000 claims 2
- 241000589876 Campylobacter Species 0.000 claims 2
- 241000589516 Pseudomonas Species 0.000 claims 2
- 241000607768 Shigella Species 0.000 claims 2
- 241000589875 Campylobacter jejuni Species 0.000 claims 1
- 102000009016 Cholera Toxin Human genes 0.000 claims 1
- 108010049048 Cholera Toxin Proteins 0.000 claims 1
- 108010089072 Dolichyl-diphosphooligosaccharide-protein glycotransferase Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 241000607764 Shigella dysenteriae Species 0.000 claims 1
- 229940007046 shigella dysenteriae Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (17)
1. Uporaba jedne ili više sekvenci aminokiselina koje sadrže sekvencu D/E- X- N-Z-S/T, gdje X i Z mogu biti bilo koja prirodna aminokiselina osim prolina, za modificiranje proteina tako da oligosaharil transferaza iz Campylobacter spp. može taj protein N-glikozilirati.
2. Uporaba prema zahtjevu 1, gdje se protein modificira uvođenjem te jedne ili više aminokiselina u taj protein.
3. Uporaba prema zahtjevu 1, gdje se protein modificira dodavanjem, brisanjem i/ili zamjenom jedne ili više aminokiselina u tom proteinu.
4. Uporaba prema bilo kojem od zahtjeva 1 do 3, gdje Campylobacter spp. jest C. jejuni.
5. Uporaba prema bilo kojem od zahtjeva 1 do 4, gdje protein dalje obuhvaća glikan vezan za svaku od te jedne ili više uvedenih konsenzus sekvenci preko N-glikozidne veze.
6. Uporaba prema bilo kojem od zahtjeva 1 do 5, gdje je taj protein P. aeruginosa egzoprotein.
7. Uporaba prema zahtjevu 7, gdje taj P. aeruginosa egzoprotein ima dvije te uvedene konsenzus sekvence.
8. Uporaba prema zahtjevu 5, gdje taj glikan ima oligo- ili polisaharid iz Gram-negativne bakterije.
9. Uporaba prema zahtjevu 8, gdje je taj oligo- ili polisaharid iz Shigella spp, Pseudomonas spp ili E. coli.
10. Uporaba prema zahtjevu 9, gdje taj Shigella spp. jest Shigella dysenteriae O1.
11. Uporaba prema zahtjevu 9, gdje taj Pseudomonas spp. jest P. aeruginosa.
12. Uporaba prema zahtjevu 11, gdje taj P. aeruginosa jest P. aeracginosa O11.
13. Uporaba prema zahtjevu 5, gdje taj glikan ima oligo- ili polisaharid iz Gram-pozitivne bakterije.
14. Uporaba prema zahtjevu 1, gdje taj protein obuhvaća barem dvije te uvedene konsenzus sekvence.
15. Uporaba prema zahtjevu 14, gdje je barem jedan od tih glikana različit od drugih glikana.
16. Uporaba prema zahtjevu 1, gdje taj protein jest CRM.
17. Uporaba prema zahtjevu 1, gdje taj protein jest Cholera toksin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05010276 | 2005-05-11 | ||
| EP10179208.3A EP2311972B1 (en) | 2005-05-11 | 2006-05-10 | Recombinant N-glycosylated proteins from procaryotic cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150312T1 true HRP20150312T1 (hr) | 2015-07-31 |
Family
ID=37396912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150312TT HRP20150312T1 (hr) | 2005-05-11 | 2015-03-18 | Rekombinantni n-glikozilirani proteini iz prokariotskih stanica |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8753864B2 (hr) |
| EP (3) | EP1888761B1 (hr) |
| JP (3) | JP5356807B2 (hr) |
| KR (2) | KR101524636B1 (hr) |
| CN (2) | CN101360831B (hr) |
| AT (1) | ATE483027T1 (hr) |
| AU (1) | AU2006245969B8 (hr) |
| CA (1) | CA2607595C (hr) |
| CY (1) | CY1116285T1 (hr) |
| DE (1) | DE602006017207D1 (hr) |
| DK (2) | DK2311972T3 (hr) |
| ES (3) | ES2703061T3 (hr) |
| HK (3) | HK1113588A1 (hr) |
| HR (1) | HRP20150312T1 (hr) |
| IL (2) | IL187293A (hr) |
| PL (1) | PL2311972T3 (hr) |
| PT (2) | PT2311972E (hr) |
| SI (1) | SI2311972T1 (hr) |
| WO (1) | WO2006119987A2 (hr) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| DE60303591T2 (de) | 2002-03-07 | 2007-03-01 | Eidgenössische Technische Hochschule Zürich | System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen |
| MXPA05010773A (es) | 2003-04-09 | 2005-12-12 | Neose Technologies Inc | Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos. |
| US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| ES2560657T3 (es) | 2004-01-08 | 2016-02-22 | Ratiopharm Gmbh | Glicosilación con unión en O de péptidos G-CSF |
| NZ593986A (en) * | 2004-03-03 | 2013-07-26 | Revance Therapeutics Inc | Compositions comprising a protein and a carrier for topical diagnostic and therapeutic transport |
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
| EP1814573B1 (en) | 2004-10-29 | 2016-03-09 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
| ES2449195T3 (es) | 2005-01-10 | 2014-03-18 | Ratiopharm Gmbh | Factor estimulante de colonias de granulocitos glicopegilado |
| CN106039294A (zh) * | 2005-03-03 | 2016-10-26 | 雷文斯治疗公司 | 用于局部施用和经皮肤递送肉毒杆菌毒素的组合物和方法 |
| WO2006121569A2 (en) | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| JP5216580B2 (ja) | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー／エス | グリコペグ化第ｉｘ因子 |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| WO2008011633A2 (en) | 2006-07-21 | 2008-01-24 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
| CN101796063B (zh) | 2007-04-03 | 2017-03-22 | 拉蒂奥法姆有限责任公司 | 使用糖聚乙二醇化g‑csf的治疗方法 |
| ES2551123T3 (es) | 2007-06-12 | 2015-11-16 | Ratiopharm Gmbh | Proceso mejorado para la producción de azúcares de nucleótido |
| WO2009089154A2 (en) | 2008-01-03 | 2009-07-16 | Cornell Research Foundation, Inc. | Glycosylated protein expression in prokaryotes |
| EP2242505A4 (en) * | 2008-01-08 | 2012-03-07 | Biogenerix Ag | GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES |
| EP3427749A1 (en) * | 2008-02-20 | 2019-01-16 | GlaxoSmithKline Biologicals SA | Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells |
| JP5619630B2 (ja) | 2008-02-27 | 2014-11-05 | ノボ・ノルデイスク・エー／エス | 結合型第ｖｉｉｉ因子分子 |
| PL2411503T3 (pl) * | 2009-03-27 | 2018-01-31 | Eidgenoessische Technische Hochschule Zuerich | Salmonella enterica prezentująca n-glikan z c. jejuni lub jego pochodne |
| KR101855380B1 (ko) * | 2009-11-19 | 2018-05-08 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 원핵세포에서 면역원성 폴리사카라이드를 제조하는 생합성 시스템 |
| JP5925699B2 (ja) | 2010-02-11 | 2016-05-25 | ザ・ガバナーズ・オブ・ザ・ユニバーシティー・オブ・アルバータ | Ｎ結合型グリカン化合物 |
| KR20130063510A (ko) | 2010-05-06 | 2013-06-14 | 글리코박신 아게 | 캡슐형 그람-양성 세균 생체접합체 백신 |
| JP2013539963A (ja) * | 2010-09-03 | 2013-10-31 | ザ ガバナーズ オブ ザ ユニバーシティ オブ アルバータ | 複数のｎ結合型グリコシル化シークオンを含んでいるペプチド |
| AU2012306345A1 (en) | 2011-09-06 | 2014-03-20 | Glycovaxyn Ag | Bioconjugate vaccines made in prokaryotic cells |
| CA3125293A1 (en) | 2012-11-07 | 2014-05-15 | Glaxosmithkline Biologicals Sa | Production of recombinant vaccine in e. coli by enzymatic conjugation |
| EP2945651B1 (en) | 2013-01-17 | 2018-03-07 | ARSANIS Biosciences GmbH | Mdr e. coli specific antibody |
| US9931392B2 (en) | 2013-01-18 | 2018-04-03 | London School Of Hygiene And Tropical Medicine | Glycosylation method |
| GB201301085D0 (en) | 2013-01-22 | 2013-03-06 | London School Hygiene & Tropical Medicine | Glycoconjugate Vaccine |
| MX357888B (es) * | 2013-03-15 | 2018-07-27 | Asieris Pharmaceutical Tech Co Ltd | Sales basicas de adicion de nitroxolina y usos de las mismas. |
| ES2753369T3 (es) * | 2013-04-05 | 2020-04-08 | Univ Alberta | Vacuna de Campylobacter |
| CN106062203B (zh) * | 2013-10-11 | 2020-08-07 | 葛兰素史密丝克莱恩生物有限公司 | 宿主细胞修饰的方法 |
| CN106535927B (zh) | 2014-02-24 | 2019-09-20 | 葛兰素史密丝克莱恩生物有限公司 | 新颖多糖及其用途 |
| CA2945542C (en) | 2014-04-17 | 2024-03-05 | Glycovaxyn Ag | Modified host cells and uses thereof |
| CN106795545A (zh) | 2014-08-08 | 2017-05-31 | 格林考瓦因有限公司 | 用于生物缀合物产生的修饰宿主细胞和杂合寡糖 |
| LT3240895T (lt) * | 2014-12-30 | 2022-04-11 | Glaxosmithkline Biologicals S.A. | Kompozicijos ir būdai, skirti baltymų glikozilinimui |
| TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
| GB201518668D0 (en) * | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
| GB201610599D0 (en) | 2016-06-17 | 2016-08-03 | Glaxosmithkline Biologicals Sa | Immunogenic Composition |
| AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
| BR112019015425A2 (pt) | 2017-01-27 | 2020-05-26 | University Of Florida Research Foundation, Incorporated | Uma vacina de segurança alimentar para controlar salmonella enterica e reduzir campylobacter em aves domésticas |
| GB201712678D0 (en) | 2017-08-07 | 2017-09-20 | Glaxosmithkline Biologicals Sa | Process for the manipulation of nucleic acids |
| US11898187B2 (en) | 2017-08-15 | 2024-02-13 | Northwestern University | Protein glycosylation sites by rapid expression and characterization of N-glycosyltransferases |
| GB201721582D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | S aureus antigens and immunogenic compositions |
| GB201721576D0 (en) | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
| WO2019175147A1 (en) | 2018-03-12 | 2019-09-19 | Janssen Vaccines & Prevention B.V. | Vaccines against intra-abdominal infections |
| US11530432B2 (en) | 2018-03-19 | 2022-12-20 | Northwestern University | Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates |
| WO2019204346A1 (en) | 2018-04-16 | 2019-10-24 | Northwestern University | METHODS FOR CO-ACTIVATING IN VITRO NON-STANDARD AMINO ACID (nsAA) INCORPORATION AND GLYCOSYLATION IN CRUDE CELLLYSATES |
| US20220054632A1 (en) | 2018-12-12 | 2022-02-24 | Glaxosmithkline Biologicals Sa | Modified carrier proteins for o-linked glycosylation |
| HRP20231026T1 (hr) | 2019-03-18 | 2023-12-08 | Janssen Pharmaceuticals, Inc. | Postupci za proizvodnju biokonjugata polisaharida o-antigena e. coli, njihovi pripravci i postupci njihove primjene |
| CN113924112A (zh) | 2019-03-18 | 2022-01-11 | 杨森制药公司 | 大肠杆菌o-抗原多糖的生物缀合物、其生产方法及其使用方法 |
| EP3757217A1 (en) | 2019-06-27 | 2020-12-30 | GlaxoSmithKline Biologicals S.A. | Methods for protein purification |
| EP3770269A1 (en) | 2019-07-23 | 2021-01-27 | GlaxoSmithKline Biologicals S.A. | Quantification of bioconjugate glycosylation |
| EP3777884A1 (en) | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| JP7485771B2 (ja) | 2020-01-16 | 2024-05-16 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | ＦｉｍＨ変異体、その組成物、及びその使用 |
| JP2023530154A (ja) | 2020-06-18 | 2023-07-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 赤痢菌４価（Ｓｈｉｇｅｌｌａ４Ｖ）バイオコンジュゲート |
| CA3185639A1 (en) | 2020-06-25 | 2021-12-30 | Glaxosmithkline Biologicals Sa | Vaccine |
| PE20231385A1 (es) | 2020-09-17 | 2023-09-12 | Janssen Pharmaceuticals Inc | Composiciones de vacunas multivalentes y usos de las mismas |
| MX2023008251A (es) | 2021-01-12 | 2023-07-26 | Janssen Pharmaceuticals Inc | Mutantes de fimh, composiciones con estos y uso de estos. |
| UY39710A (es) | 2021-04-01 | 2022-09-30 | Janssen Pharmaceuticals Inc | Producción de bioconjugados de o18 de e. coli |
| WO2023118033A1 (en) | 2021-12-22 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Vaccine |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0170204B1 (de) | 1984-08-01 | 1991-09-25 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen |
| US5643758A (en) | 1987-03-10 | 1997-07-01 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
| WO1994026906A2 (en) | 1993-05-14 | 1994-11-24 | The Upjohn Company | CLONED DNA ENCODING A UDP-GALNAc:POLYPEPTIDE,N-ACETYLGALACTOS AMINYLTRANSFERASE |
| US6503744B1 (en) | 1999-02-01 | 2003-01-07 | National Research Council Of Canada | Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics |
| CA2363297C (en) | 1999-03-02 | 2011-08-09 | Michael J. Betenbaugh | Engineering intracellular sialylation pathways |
| US20020127219A1 (en) * | 1999-12-30 | 2002-09-12 | Okkels Jens Sigurd | Lysosomal enzymes and lysosomal enzyme activators |
| MXPA02011016A (es) | 2000-05-12 | 2004-03-16 | Neose Technologies Inc | Glicopeptidos recombinantes de glucolisacion in vitro. |
| US6803225B2 (en) | 2000-06-30 | 2004-10-12 | Flanders Interuniversity Institute For Biotechnology | Protein glycosylation modification in Pichia pastoris |
| DE10113573A1 (de) | 2001-03-20 | 2002-02-28 | Messer Griesheim Gmbh | Verfahren zum Regenerieren von Schwefelsäure aus schwefelhaltigen Reststoffen |
| DE60303591T2 (de) | 2002-03-07 | 2007-03-01 | Eidgenössische Technische Hochschule Zürich | System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen |
| KR20100119905A (ko) | 2002-03-07 | 2010-11-11 | 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 | 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계 |
| ES2391525T3 (es) | 2002-08-01 | 2012-11-27 | National Research Council Of Canada | Glucanos y glucopéptidos de Campylobacter |
-
2006
- 2006-05-10 DE DE602006017207T patent/DE602006017207D1/de active Active
- 2006-05-10 US US11/920,175 patent/US8753864B2/en active Active
- 2006-05-10 CN CN200680020861XA patent/CN101360831B/zh active Active
- 2006-05-10 JP JP2008510495A patent/JP5356807B2/ja active Active
- 2006-05-10 ES ES14199949T patent/ES2703061T3/es active Active
- 2006-05-10 EP EP06753552A patent/EP1888761B1/en active Active
- 2006-05-10 WO PCT/EP2006/004397 patent/WO2006119987A2/en active Application Filing
- 2006-05-10 DK DK10179208T patent/DK2311972T3/en active
- 2006-05-10 KR KR1020147001671A patent/KR101524636B1/ko active IP Right Grant
- 2006-05-10 CA CA2607595A patent/CA2607595C/en active Active
- 2006-05-10 EP EP10179208.3A patent/EP2311972B1/en active Active
- 2006-05-10 KR KR1020077028970A patent/KR101408653B1/ko active IP Right Grant
- 2006-05-10 AU AU2006245969A patent/AU2006245969B8/en active Active
- 2006-05-10 DK DK06753552.6T patent/DK1888761T3/da active
- 2006-05-10 CN CN201310241471.7A patent/CN103396478B/zh active Active
- 2006-05-10 ES ES10179208.3T patent/ES2535084T3/es active Active
- 2006-05-10 PT PT101792083T patent/PT2311972E/pt unknown
- 2006-05-10 ES ES06753552T patent/ES2353814T3/es active Active
- 2006-05-10 EP EP14199949.0A patent/EP2853600B1/en active Active
- 2006-05-10 PL PL10179208T patent/PL2311972T3/pl unknown
- 2006-05-10 SI SI200631910T patent/SI2311972T1/sl unknown
- 2006-05-10 AT AT06753552T patent/ATE483027T1/de active
- 2006-05-10 PT PT06753552T patent/PT1888761E/pt unknown
-
2007
- 2007-11-11 IL IL187293A patent/IL187293A/en active IP Right Grant
-
2008
- 2008-08-14 HK HK08109020.7A patent/HK1113588A1/xx unknown
-
2011
- 2011-10-19 HK HK11111186.8A patent/HK1156983A1/zh unknown
-
2012
- 2012-01-06 JP JP2012001342A patent/JP5687637B2/ja active Active
-
2013
- 2013-06-10 IL IL226857A patent/IL226857A/en not_active IP Right Cessation
- 2013-12-03 JP JP2013250586A patent/JP5827303B2/ja active Active
-
2014
- 2014-02-06 US US14/174,742 patent/US9551019B2/en active Active
-
2015
- 2015-03-18 HR HRP20150312TT patent/HRP20150312T1/hr unknown
- 2015-04-15 CY CY20151100351T patent/CY1116285T1/el unknown
- 2015-06-09 HK HK15105466.7A patent/HK1205193A1/xx unknown
-
2016
- 2016-05-19 US US15/159,535 patent/US20160326563A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150312T1 (hr) | Rekombinantni n-glikozilirani proteini iz prokariotskih stanica | |
| Logan | Flagellar glycosylation–a new component of the motility repertoire? | |
| Rizzato et al. | Potential role of biofilm formation in the development of digestive tract cancer with special reference to Helicobacter pylori infection | |
| Lee et al. | Proteomics in gram‐negative bacterial outer membrane vesicles | |
| Siciliano et al. | Molecular mechanisms of probiotic action: a proteomic perspective | |
| DK2343320T3 (da) | Anti-gitr-antistoffer og anvendelser deraf | |
| ES2684129T3 (es) | Bioconjugados preparados a partir de proteínas N-glicosiladas recombinantes procedentes de células procariotas | |
| Glew et al. | PorV is an outer membrane shuttle protein for the type IX secretion system | |
| Juodeikis et al. | Outer membrane vesicles: biogenesis, functions, and issues | |
| MY157915A (en) | Anti-il-12 antibodies, epitopes, compositions, methods and uses. | |
| DK1347730T3 (da) | Rekombinante anti-CD30-antistoffer og anvendelser deraf | |
| BRPI0620946B8 (pt) | anticorpo il-23p19 isolado, composição, método in vitro, artigo de fabricação, molécula e vetor de ácido nucleico, célula hospedeira procariótica | |
| WO2004099231A3 (en) | Glycopegylation methods and proteins/peptides produced by the methods | |
| EA201001883A1 (ru) | Мутанты fgf21 и их применение | |
| WO2008011633A3 (en) | Glycosylation of peptides via o-linked glycosylation sequences | |
| NO20053304L (no) | NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse | |
| Parc et al. | A novel endo‐β‐N‐acetylglucosaminidase releases specific N‐glycans depending on different reaction conditions | |
| ATE438409T1 (de) | Proteinhaltigen vektoren zur einführung von moleküle in cd11b exprimirende zellen | |
| CN108368051B (zh) | 三官能交联试剂 | |
| Vorkapic et al. | A broad spectrum protein glycosylation system influences type II protein secretion and associated phenotypes in Vibrio cholerae | |
| DE602004032144D1 (de) | Für fructooligosaccharid-nutzende verbindungen codierende nukleinsäuren aus lactobacillus acidophilus und verwendungen davon | |
| EP2098594A4 (en) | NUCLEIC ACID MOLECULE CAPABLE OF BINDING A BIT-DARNED IGG ANTIBODY | |
| US20220226430A1 (en) | Protein inhibitors of clostridium difficile toxin b | |
| WO2009094006A3 (en) | Bordetella outer-membrane protein antigens and methods of making and using the same | |
| AU2011218682A1 (en) | Recombinant N-glycosylated proteins from procaryotic cells |